The Current Landscape of Prostate-Specific Membrane Antigen (PSMA) Imaging Biomarkers for Aggressive Prostate Cancer

Author(s): Al Saffar, H; Chen, DC; Delgado, C; Ingvar, J; Hofman, MS; Lawrentschuk, N; Perera, M; Murphy, DG; Eapen, R;
Details: Publication Year 2024-02-26,Volume 16,Issue #5,Page 939
Journal Title: Cancers
Publication Type: Review
Abstract: The review examines the vital role of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the diagnosis, staging, and treatment of prostate cancer (PCa). It focuses on the superior diagnostic abilities of PSMA PET/CT for identifying both nodal and distant PCa, and its potential as a prognostic indicator for biochemical recurrence and overall survival. Additionally, we focused on the variability of PSMA's expression and its impact on personalised treatment, particularly the use of [(177)Lu] Lu-PSMA-617 radioligand therapy. This review emphasises the essential role of PSMA PET/CT in enhancing treatment approaches, improving patient outcomes, and reducing unnecessary interventions, positioning it as a key element in personalised PCa management.
Publisher: MDPI
Keywords: Psma pet/ct; aggressive prostate cancer; biochemical recurrence; prostate-specific membrane antigen; uro-oncology
Department(s): Surgical Oncology; Cancer Imaging
Publisher's Version: https://doi.org/10.3390/cancers16050939
Open Access at Publisher's Site: https://doi.org/10.3390/cancers16050939
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2024-03-28 06:48:05

Last Modified: 2024-03-28 06:51:46